+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of the role of pharmacy technicians in reviewing the eligibility for Oncotype DX genomic test and the impact of the test on treatment plans in breast cancer patients



Evaluation of the role of pharmacy technicians in reviewing the eligibility for Oncotype DX genomic test and the impact of the test on treatment plans in breast cancer patients



Journal of Oncology Pharmacy Practice 25(5): 1167-1173



The Oncotype DX genomic test is a treatment decision-making tool. Test results are presented as recurrence scores which are used to help decide between adjuvant hormonal therapy (low recurrence score) or chemotherapy (high recurrence score). Since 2014, the Oncotype DX test has been funded at the cancer treatment centres in our province for patients with early breast cancer. Eligibility criteria for funding include patient and tumour characteristics. Pharmacy technicians were assigned to review and approve requests based on the eligibility criteria and with access to consultation to an oncology pharmacist and a medical oncologist. We assessed the clinical role of pharmacy technicians in this review process and the impact of recurrence score on treatment decisions. This was a retrospective, multi-centre study to evaluate the Oncotype DX test eligibility review process from June 2014 to May 2015. The main objectives were to assess (1) the discrepancy rate of approval by the pharmacy technicians in this review process and (2) the concordance rate between the recurrence score from the Oncotype DX test and the adjuvant treatment given. Four hundred and forty requests for Oncotype DX test were received during the study period. A total of 90.8% of requests were approved and 9.2% were denied. The discrepancy rate of approval by pharmacy technicians was 1.1%. The average review time was 13.8 min, with the reviewing pharmacist and oncologist consulted in 5.5 and 15.2% of the requests, respectively. The concordance rate between the recurrence score and given treatment was 96%. The discrepancy rate of our pharmacy technicians appears to be similar to that reported with other expanded technician roles in literature, suggesting that the current task and other similar clinical tasks can be reliably delegated to technicians. The concordance rate of the recurrence score and given treatment in our study was higher than what has been reported in literature, suggesting that most of our patients were treated in accordance to recurrence score-based recommendations. Pharmacy technicians were able to expand their clinical role by accurately reviewing the Oncotype DX test requests with a low discrepancy rate. The Oncotype DX test results appeared to successfully guide the adjuvant treatment given to patients in accordance to recurrence score-based recommendations.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065780014

Download citation: RISBibTeXText

PMID: 30348071

DOI: 10.1177/1078155218803703


Related references

Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer. Breast Cancer 9: 393-400, 2017

The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer. Medical Journal of Australia 199(3): 205-208, 2013

The impact of a genomic assay (Oncotype Dx) on adjuvant treatment recommendations in early breast cancer. The Medical Journal of Australia 199(3): 205-208, 2013

Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clinical Chemistry 53(6): 1084-1091, 2007

Economic Impact of a Genomic Companion Diagnostic Test for Breast Cancer Patients in French Private Hospitals. Value in Health 17(7): A623, 2014

Cost effectiveness of Oncotype DX test in patients with early-stage breast cancer in a middle-income country, Turkey: results of a prospective multicenter study. Breast 32: S84-S85, 2017

Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX ® Breast Recurrence Score Assay. European Journal of Surgical Oncology 43(5): 921-930, 2017

Oncotype DX Gene Test Seen Changing Over One-Third of Early Breast Cancer Decisions. Oncology Times 33(12): 10-11, 2011

Disparities in compliance with the Oncotype DX breast cancer test in the United States: A National Cancer Data Base assessment. American Journal of Surgery 215(4): 686-692, 2018

Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer. Plos one 8(3): E58483, 2013

Impact of Oncotype DX testing on adjuvant treatment decisions in patients with early breast cancer: a single-center study in the United Arab Emirates. Asia-Pacific Journal of Clinical Oncology 10(4): 354-360, 2014

Comparison between Oncotype DX test and standard prognostic criteria in estrogen receptor positive early-stage breast cancer. Einstein 9(3): 354-358, 2011

Evaluation of practice patterns in the treatment of node-negative, hormone-receptor positive breast cancer patients with the use of the oncotype DX assay at the University of Pennsylvania. 2007

The impact of the Oncotype DX Recurrence Score on treatment decisions and clinical outcomes in patients with early breast cancer: the Maccabi Healthcare Services experience with a unified testing policy. Ecancermedicalscience 7: 380, 2013

The Impact of the Oncotype DX Breast Cancer Assay on Treatment Decisions for Women With Estrogen Receptor-Positive, Node-Negative Breast Carcinoma in Hong Kong. Clinical Breast Cancer 16(5): 372-378, 2016